评估坦索罗辛在延迟后尿道瓣膜患者进展至清洁间歇导尿和终末期肾病中的效用:我们是否在推迟不可避免之事?
本研究基于2000年1月至2022年1月的前瞻性机构数据库,回顾179例后尿道瓣膜患者,比较接受坦索罗辛(59例)与未接受(120例)者进展至清洁间歇导尿(CIC)、透析或肾移植的差异。Kaplan-Meier曲线显示坦索罗辛组进展至CIC的可能性更低(P=.021),但透析或肾移植无差异;Cox回归显示坦索罗辛延迟CIC进展(HR 0.444,95%CI 0.218-0.902,P=.025)。结论认为坦索罗辛可能延迟CIC,但似乎不延迟终末期肾病进展。
要点
- 坦索罗辛组较未用药组进展至清洁间歇导尿的可能性更低(P=.021)。
- 两组进展至透析或肾移植无差异。
- 校正基线特征后,坦索罗辛延迟CIC进展(HR 0.444,95%CI 0.218-0.902,P=.025)。
核心结论
- 坦索罗辛可能延迟清洁间歇导尿,但似乎不延迟终末期肾病进展。
- 需要进一步研究特定患者因素以确定用药时机和可能最大获益的亚组。
研究设计与样本
- 回顾性分析前瞻性机构数据库,纳入2000年1月至2022年1月治疗的后尿道瓣膜患者179例。
- 59例在开始CIC前接受坦索罗辛(组1),120例未接受(组2)。
主要发现
- 两组基线特征相似,仅抗胆碱能药物使用有差异(坦索罗辛组35/59 vs 无坦索罗辛组32/120,P<.001)。
- 坦索罗辛起始中位年龄26.0个月(IQR 15.5-48.6),从起始至进展CIC的中位时间52.6个月(IQR 10.1-69.3)。
- Kaplan-Meier曲线显示坦索罗辛组进展至CIC的可能性更低(P=.021),但透析或肾移植进展无差异。
- Cox回归校正年龄、抗胆碱能药物使用、膀胱输尿管反流严重程度和1岁时CKD分期后,坦索罗辛延迟CIC进展(HR 0.444,95%CI 0.218-0.902,P=.025)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether tamsulosin may aid emptying of the lower urinary tract in posterior urethral valves patients, mitigating the likelihood of progressing to clean intermittent catheterization (CIC) or need for renal replacement therapy. METHODS: We reviewed a prospective institutional database containing posterior urethral valves patients treated between January 2000 and January 2022. After assessing baseline characteristics, Kaplan-Meier survival curves and log-rank tests were generated to assess differences in clinically significant outcomes (progression to CIC, dialysis, or kidney transplantation) between those prescribed tamsulosin and those who were not. RESULTS: A total of 179 patients were included. Fifty-nine patients received tamsulosin prior to initiation of CIC (group 1), and 120 did not (group 2). The baseline characteristics were similar between the two groups, except for anticholinergic use (tamsulosin group - 35/59 vs no tamsulosin - 32/120, P < .001). The median age at tamsulosin initiation was 26.0 months (IQR 15.5-48.6) and the median time from initiation of tamsulosin to progression to CIC was 52.6 months (IQR 10.1-69.3). Kaplan-Meier survival curves showed that patients on tamsulosin were less likely to progress to CIC (P = .021), however, there was no difference in progression to dialysis or kidney transplantation. A Cox-regression analysis controlling for baseline characteristics, including age, anticholinergic use, vesicoureteral reflux severity, and CKD stage at 1-year of life, showed a consistent effect of tamsulosin in delaying progression to CIC (HR 0.444 95%CI 0.218-0.902, P = .025). CONCLUSION: While tamsulosin may delay CIC, it does not appear to delay progression to end-stage renal disease. Additional studies exploring specific patient factors are required to determine the timing and subset who may benefit the most from tamsulosin.
引用
- Kim JK, Khondker A, Chua ME, et al. Assessing the Utility of Tamsulosin in Delaying Progression to Clean Intermittent Catheterization and End-stage Renal Disease in Patients With Posterior Urethral Valves: Are We Postponing the Inevitable? Urology. 2023. PMID: 37348660. doi:10.1016/j.urology.2023.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。